1314 E LAS OLAS BLVD, SUITE 221, FORT LAUDERDALE, FL
Receives NYSE American Acceptance of Compliance Plan, Establishing Defined Path Toward Continued Listing and Strategic Transformation
Exclusive License Agreement with Argent Biopharma for CannEpil®
Acquires Exclusive Global Rights to CannEpil®, an Epilepsy Therapy with Established European Patient Access, FDA Engagement and U.S. Development Potential
Unregistered Sales of Equity Securities
Invests in Avicanna, a Leading Cannabinoid Biopharmaceutical Platform, Advancing Its Transformation into Cannabinoid Healthcare
Material disclosure
Provides Corporate Update on NYSE Compliance Process and Strategic Transaction Initiatives
Q1
Amended Annual Report
FY 2025
Notice of Late Filing for Annual Report
Q3
Notice of Late Filing for Quarterly Report
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
S-1
Registration Statement for Securities to be Offered to Employees
RW
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
PRER14A
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Definitive Revised Proxy Statement
Submission Upload
Correspondence